哮喘医疗负担评分:严重度衡量与缓解预测
基于SARP III和U-BIOPRED两个纵向队列,构建整合急性发作、医疗资源使用及SABA使用的复合负担评分。该评分与肺功能、哮喘控制和生活质量负相关,≤0·15可高敏感度与高特异度预测哮喘缓解,且与现行严重哮喘定义存在明显差异。
要点
- 负担评分整合急性发作、医疗资源使用和SABA使用,体现以患者为中心的疾病负担。
- 评分≤0·15预测哮喘缓解的敏感度>91%、特异度99%。
- 现行基于处方的严重哮喘定义与负担评分存在明显不一致。
核心结论
- 基于医疗负担的复合评分可反映哮喘严重度并准确预测缓解,与ERS-ATS及GINA基于处方的严重度定义存在明显差异。
- 经前瞻性验证后,该评分可能有助于优化高危哮喘患者的管理。
研究设计与样本
- 分析SARP III(美国)与U-BIOPRED(11个欧洲国家)两个纵向队列的前瞻性数据,构建基于急性发作与医疗资源使用并纳入SABA使用的复合负担评分。
主要发现
- SARP III纳入528例成人哮喘,平均随访4·4年(SD 1·6),312例(59%)按ERS-ATS定义为严重哮喘。
- SARP III中205例每日使用急救SABA,其中90例每日使用两次及以上。
- U-BIOPRED纳入509例成人哮喘,随访1年,421例(83%)为严重哮喘。
- 严重哮喘者中负担评分低于1·29每患者年的比例:SARP III为106/312(34%),U-BIOPRED为80/421(19%)。
- 非严重哮喘者中负担评分高于中位值的比例:SARP III为58例(28%),U-BIOPRED为24例(27%)。
关键数值与推荐
- 两队列中负担评分与肺功能、哮喘控制和生活质量均呈负相关。
- 负担评分≤0·15预测哮喘缓解的敏感度>91%、特异度99%。
临床怎么用
- 可将医疗负担评分用于识别现行严重度定义下仍属高负担的哮喘患者,并辅助预判缓解可能性。
局限性
- 负担评分尚需前瞻性验证,当前结论基于两个队列的回顾性分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Current asthma guidelines, including those of the European Respiratory Society (ERS) and American Thoracic Society (ATS), suboptimally predict asthma remission, disease severity, and health-care utilisation. We aimed to establish a novel approach to assess asthma severity based on asthma health-care burden data. METHODS: We analysed prospectively collected data from the Severe Asthma Research Program III (SARP III; USA) and the European Unbiased Biomarkers for the Prediction of Respiratory Disease Outcomes (U-BIOPRED; 11 European countries) to calculate a composite burden score based on asthma exacerbations and health-care utilisation, which was modified to include the use of short-acting beta agonists (SABAs) to reflect asthma symptom burden. FINDINGS: In SARP III, 528 adult participants with asthma were followed up for a mean of 4·4 (SD 1·6) years, and 312 (59%) had severe asthma according to the ERS-ATS definition. Among the 205 participants with asthma who used rescue SABAs daily, 90 used these two or more times a day. In U-BIOPRED, 509 adult participants with asthma were followed up for 1 year, and 421 (83%) had severe asthma. The burden score was less than 1·29 per patient-year in 106 (34%) of 312 SARP III participants and in 80 (19%) of 421 U-BIOPRED participants with severe asthma. By contrast, the burden score was above the median value in 58 (28%) SARP III and 24 (27%) U-BIOPRED participants with non-severe asthma. In both cohorts, the burden score negatively correlated with lung function, asthma control, and quality of life. A burden score of 0·15 or lower predicted asthma remission with a sensitivity greater than 91% and a specificity of 99%. INTERPRETATION: Our findings highlight considerable discrepancies between the current definition of asthma severity and our burden score. Although the definition of severe asthma proposed by the ERS-ATS and the and Global Initiative for Asthma (GINA) is based on prescribed asthma medications, our personalised health-care burden score includes patient-centred data that reflect disease severity and accurately predicts asthma remission. Subject to prospective validation, the burden score could help to optimise the management of high-risk individuals with asthma. FUNDING: SARP III: US National Heart, Lung, and Blood Institute; AstraZeneca; Boehringer Ingelheim; Genentech; GlaxoSmithKline; Sanofi Genzyme/Regeneron; and Teva Pharmaceuticals. U-BIOPRED: Innovative Medicines Initiative Joint Undertaking (EU's Seventh Framework Programme and European Federation of Pharmaceutical Industries and Associations) and eTRIKS project.
引用
- Zein JG, Zounemat-Kerman N, Adcock IM, et al. Development of an asthma health-care burden score as a measure of severity and predictor of remission in SARP III and U-BIOPRED: results from two major longitudinal asthma cohorts. Lancet Respir Med. 2024. PMID: 39586307. doi:10.1016/S2213-2600(24)00250-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。